Compounds > n-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide
Page last updated: 2024-09-05

n-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide and Diffuse Parenchymal Lung Disease

n-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide has been researched along with Diffuse Parenchymal Lung Disease in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baba, T; Chino, H; Itoh, H; Iwasawa, T; Ogura, T; Okudela, K; Sato, S; Sekine, A; Suzuki, Y; Takemura, T1

Other Studies

1 other study(ies) available for n-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide and Diffuse Parenchymal Lung Disease

ArticleYear
Radiological and Pathological Correlation in Anti-MDA5 Antibody-positive Interstitial Lung Disease: Rapidly Progressive Perilobular Opacities and Diffuse Alveolar Damage.
    Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:16

    Topics: Autoantibodies; Biomarkers; Cyclic N-Oxides; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Pulmonary Alveoli; Tomography, X-Ray Computed

2016